BARDA

CBRN helps innovators develop promising MCMs from preclinical development to clinical trials and manufacturing scale-up to FDA approval.

CMA provides flexible and innovative acquisition solutions in support of BARDA’s mission. CMA strives to enhance the U.S. government’s contracting capabilities to respond quickly to both known and emerging public health threats.

DDDI invests in diagnostics and devices across the spectrum of advanced research and development, stockpiling, and domestic manufacturing capacity expansion.

DNCD provides nonclinical models, tools, and expertise to advance MCM development. DNCD provides expertise and laboratory capacity to establish and share nonclinical models, conduct appropriate nonclinical studies to support FDA approval, and evaluate potential MCM candidates prior to BARDA investment.

DRIVe works to accelerate the development and availability of transformative technologies and approaches to protect Americans from health security threats. DRIVe aims to de-risk the most promising technologies and capabilities.

Influenza & EID invests in advanced research and development, manufacturing capacity, and procurement of MCMs to protect the nation from pandemic influenza and other emerging infectious diseases.

PCI provides expertise to strengthen the nation’s ability to manufacture, distribute, administer, and scale production of lifesaving MCMs.

RQA ensures that BARDA-supported MCMs are safe, effective, and in compliance with relevant and current laws, regulations, and guidelines by providing technical expertise and innovative regulatory and policy approaches.